Document is current

Article History

Received: 4 April 2023

Revised: 17 August 2023

Accepted: 22 August 2023

First Online: 5 September 2023

Declarations

:

: H.S. reports honoraria from Takeda Pharma, Ono Pharma, Novartis Pharma, Celgene, Janssen Pharma, Chugai Pharm, Sanofi, AstraZeneca, AbbVie, SymBio Pharma, Eisai and Kyowa Kirin; and research funding from Pharma Essentia Japan, Janssen Pharma, Ono Pharma, Celgene, Novartis Pharma, Sanofi, AstraZeneca, AbbVie, Eisai, HUYA Bioscience International and Chugai Pharma; and scholarship endowment from Astellas Pharma, Teijin Pharma, Shionogi, Eisai, Sanofi, Taiho Pharma, and Nippon Shinyaku. K.I. received honorarium from Bristol-Myers Squibb, Janssen Pharma, Takeda Pharma, Ono Pharma, Novartis Pharma, Kyowa Kirin, Celgene, Nippon Shinyaku, Chugai Pharma, Otsuka Pharma, Astellas Pharma, Sumitomo Dainippon Pharma and Meiji Seika Pharma. S.F. received honoraria from Takeda Pharma, Ono Pharma, Janssen Pharma, Sanofi, Bristol-Myers Squibb and Celgene. H.T. received personal fees from Bristol-Myers Squibb (Celgene), personal fees from Novartis Pharma, grants from Kyowa Kirin. J. Kanda received honorarium from Bristol-Myers Squibb, Janssen Pharma, Takeda Pharma, Sanofi and Ono Pharma, and is an advisory role in Janssen Pharma and Novartis Pharma. T.I. honorarium from Bristol-Myers Squibb, Takeda Pharma and Sanofi; and research funding from Bristol-Myers Squibb. C.S. has received personal fees from Bristol-Myers Squibb, Celgene, Janssen Pharma and Sanofi. M.H. received research funding from Chugai Pharma, Kyowa Kirin, Takeda Pharma and honoraria from Chugai Pharma, Takeda Pharma, Ono Pharma, Kyowa Kirin, Sanofi, Janssen Pharma, Novartis Pharma, Bristol-Myers Squibb. A.Takaori-Kondo serves as an advisor for Megakaryon and receives research fundings from Ono Pharma, DSK and Cognano. I.M. received personal fees from Bristol-Myers Squibb (Celgene), personal fees from Novartis Pharma, Pfizer Japan, grants and personal fees from Otsuka Pharma, during the conduct of the study; personal fees from Janssen Pharma, Amgen BioPharma, grants and personal fees from Astellas Pharma, Takeda Pharma, AbbVie GK, grants from Ono Pharma, Nippon Shinyaku, Kyowa Kirin, Sumitomo Dainippon Pharma Shionogi, Teijin Pharma, Boehringer Ingelheim, Sanofi, Chugai Pharma, Eisai, MSD, Asahi Kasei Pharma, Japan Blood Products Organization, Nihon Pharma, Taiho Pharma, Mitsubishi Tanabe Pharma, Nippon Kayaku, CSL Behring, Mundipharma, Ayumi Pharmaceutical Corporation, Eli Lilly Japan, Actelion Pharma Japan outside the submitted work. J. Kuroda received research funding from Kyowa Kirin, Chugai Pharma, Ono Pharma, Sanofi, and Bristol-Myers Squibb (BMS), has received honoraria from Janssen Pharma, Kyowa Kirin, Chugai Pharma, Ono Pharma, Sanofi, and BMS, and is a consultant for Janssen Pharma and BMS. The other authors have no conflict of interest.

: All procedures involving the patient were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.